New York, New York
Ovid Therapeutics
The Associate Director, Payroll Equity & Benefits is the go to person for anything regarding payroll and the financial side of benefits administration. This Ovidian ensures that employees are paid correctly and on time and their benefits are in sync with what they are enrolled in or changed. By managing and executing Ovid’s payroll, the PBE Administrator will be accountable for all aspects of the payroll process from time sheets to tax reporting. Ovid depends on this role to protect the company by administering payroll and benefits in a compliant fashion and should become a compliance expert. They will partner with the company’s professional employment organization (PEO) to process accurate payroll/benefits and troubleshoot when necessary. HR and the PBE Administrator team together when it comes to payroll and benefits: HR administers payroll and benefits on the front end and the PBE Administrator facilitates the appropriate processes on the back end.
CORE RESPONSIBILITIES
Payroll Administration
Benefits Administration
Accounting
Equity
COMPETENCIES
QUALIFICATIONS/SKILLS
About Us
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, we aim to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. We have built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders.
We continue to execute on our strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. Ovid’s emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed research targets. Additionally, Ovid maintains a financial interest in OV935 which is now being developed by Takeda.
EEO Statement: OVID Therapeutics is an Equal Opportunity employer. All OVID recruiting is conducted in a fair and non-discriminatory manner without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.